Immunotherapy for type 1 diabetes deemed safe in first US trial

Patients experienced no serious adverse reactions after receiving infusions of as many as 2.6 billion cells that had been specially selected to protect the body's ability to produce insulin, report scientists and physicians at the end of a trial focused on a new type 1 diabetes immunotherapy approach.